Korro Bio’s RNA-editing technology is based on research by MBL Senior Scientist Joshua Rosenthal.
By Ben Adams
Korro Bio has got off a meaty series A funding round, nabbing $91.5 million to run its platform of single-base RNA edits to treat a range of diseases.
The Cambridge, Massachusetts-based biotech will use the cash haul toward getting its preclinical program into the clinic, while also “establishing a broad portfolio of innovative RNA editing therapies.”
The financing was led by Wu Capital with help from current investors Atlas Venture and New Enterprise Associates. Additional new investors include Qiming Venture Partners USA, Surveyor Capital (a Citadel company), Cormorant Asset Management, MP Healthcare Venture Management and Alexandria Venture Investments.
Korro’s platform, known as OPERA (Oligonucleotide Promoted Editing of RNA), harnesses the body’s natural base editing system.
“OPERA can repair disease-causing mutations at the RNA level, in addition to creating therapeutically beneficial versions of proteins to improve patient outcomes,” the biotech said in a statement. This method is based upon the work of Josh Rosenthal, Ph.D., of the Marine Biological Laboratory in Massachusetts, an affiliate of the University of Chicago. Read more …
Illustration credit: Stephen Dixon